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Abstract
Introduction: Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by the abnormal accumulation of surfactant-like 
material in macrophages within the alveolar spaces and distal bronchioles. The course of the disease is variable and the prognosis 
is often good. However, progressive disease in some patients can cause respiratory dysfunction and can be life threatening. In 
this situation, the only effective treatment is whole lung lavage. 
The objective of the study was to present the characteristics and the course of pulmonary alveolar proteinosis in our own material, 
the diagnostic methods used, the indications for treatment and the treatment efficacy. 
Material and methods: Retrospective analysis included 17 patients: 6 women and 11 men, aged from 32 to 56 years, who were 
observed in the Third Lung Department of Pneumonology at the National Institute of Tuberculosis and Lung Diseases between 
1984 and 2013. In all patients chest X-ray, pulmonary function test and blood gases were performed. In 15 patients, high-resolu-
tion computed tomography (HRCT) was obtained. Bronchoscopy was performed in all of the patients, and in 7/17, bronchoalveolar 
lavage (BAL) was carried out. Fourteen patients underwent open lung biopsy. The indications for whole lung lavage (WLL) were 
progression of dyspnoea with restriction of daily activity and/or hypoxaemia. 
Results: In most of the patients (13/17) the diagnosis was established outside our institute. Patients were referred to our depart-
ment to establish further procedures. The criteria of diagnosis of PAP in most patients (16/17) was the histological examination 
of lung tissue, obtained by open lung biopsy (14 cases) and transbronchial lung biopsy (TBLB) (2 cases). Only in one patient 
the diagnosis was established on the basis of BAL. HRCT imaging was characteristic of proteinosis in 11/15 patients, and BAL 
examination in 6/7 patients, in whom BAL was performed. In four patients, who had been exposed to injurious factors for many 
years, secondary proteinosis was recognised; in other patients, no exposure or no other disease was found, and primary alveolar 
proteinosis was diagnosed. In one patient granulocyte macrophage colony stimulating factor autoantibody was detected. The 
majority of patients (10/17) had clinical symptoms at the diagnosis. The most commonly reported was dyspnoea, followed by 
respiratory tract infections. The most common abnormality (12/17) in pulmonary lung test was a decrease of diffusing capacity 
of the lung for carbon monoxide (DLCO). Respiratory distress at rest was found in two patients. Patients were observed for the 
period of 6 months to 19 years. Spontaneous partial remission was observed in 10 out of 13 untreated patients, including one 
complete remission; in 3 cases stabilisation was found in radiological examinations; and in other 4 patients, whole lung lavage 
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was used, resulting in clinical improvement with partial resolution of lesions in radiological examinations in 3 patients. In one 
patient, despite WLL being repeated three times, improvement was not achieved. 
Conclusions: Pulmonary alveolar proteinosis is a rare interstitial disease with a mild course in most cases. In 13/17 patients 
diagnosis was based on histological examination of samples from open lung biopsy. The presented patients were observed in 
the years 1984–2004, and at that time histologic examination was the main diagnostic method. The most common abnormality 
in pulmonary function tests was decrease of DLCO. In most cases, spontaneous remission of the disease was observed. In four 
patients with severe course of PAP, WLL was performed with subjective, functional and radiological improvement in 3 of them. 
Key words: pulmonary alveolar proteinosis, diagnosis, clinical course, whole lung lavage
Pneumonol. Alergol. Pol. 2014; 82: 206–217 
Streszczenie
Wstęp: Proteinoza pęcherzyków płucnych (PPP) jest rzadką chorobą charakteryzującą się nieprawidłowym gromadzeniem sub-
stancji surfaktantopodobnej w makrofagach pęcherzyków płucnych i oskrzelikach końcowych. Przebieg choroby jest różnorodny, 
a rokowanie często jest dobre. U części chorych proces jednak postępuje oraz może być przyczyną dysfunkcji układu oddecho-
wego i upośledzać jakość życia. W takiej sytuacji jedynym skutecznym leczeniem jest płukanie całych płuc. 
Celem pracy jest przedstawienie charakterystyki i przebiegu PPP w materiale własnym z prześledzeniem metod rozpoznawania 
i okoliczności kierowania chorych do Instytutu Gruźlicy i Chorób Płuc z uwzględnieniem wskazań do leczenia i oceną jego efektywności. 
Materiał i metody: Do retrospektywnej analizy włączono 17 chorych: 6 kobiet i 11 mężczyzn w wieku 32–56 lat obserwowanych 
w III Klinice Chorób Płuc Instytutu Gruźlicy w latach 1984–2013. Wszyscy chorzy mieli wykonane badania radiologiczne klatki 
piersiowej: badanie konwencjonalne (RTG) oraz 15 chorych — tomografię komputerową wysokiej rozdzielczości (HRCT), badania 
czynnościowe płuc i gazometrię. U wszystkich wykonano bronchoskopię, u 7/17 — płukanie oskrzelowo-pęcherzykowe (BAL), 
czternaścioro chorych było poddanych otwartej biopsji płuca (OBP). 
Kryteriami kwalifikującymi do płukania całych płuc (WLL) była progresja choroby z dusznością ograniczającą dzienną aktywność 
i/lub hipoksemia.
Wyniki: U 13/17 chorych rozpoznanie ustalono poza Instytutem Gruźlicy. Chorych kierowano do Instytutu Gruźlicy (IG) w celu 
ustalenia dalszego postępowania. Podstawą rozpoznania PPP było badanie histologiczne wycinków z płuca pobranych podczas 
otwartej biopsji (w 14 przypadkach) i podczas biopsji przezoskrzelowej (w 2 przypadkach). Tylko u 1 chorego rozpoznanie ustalono 
w oparciu o badanie popłuczyn oskrzelowo-pęcherzykowych. Obraz płuc w HRCT był charakterystyczny dla proteinozy w 11/15 
przypadkach, a obraz płynu z płukania oskrzelowo-pęcherzykowego w 6/7 przypadkach, w których wykonano BAL. U 4 chorych 
narażonych na czynniki szkodliwe, rozpoznano proteinozę wtórną, u pozostałych nie znaleziono narażenia na zanieczyszczenia 
środowiskowe ani choroby sprzyjającej zachorowaniu — rozpoznano zatem pierwotną proteinozę pęcherzykową. U jednej chorej 
wykryto przeciwciała przeciw czynnikowi stymulującemu dla monocytów/makrofagów (GM-CSF) w surowicy, co pozwoliło na 
rozpoznanie autoimmunologicznej postaci proteinozy (aPPP). Większość chorych (10/17) zgłaszała objawy w momencie rozpozna-
nia: duszność lub objawy zakażenia dróg oddechowych. Najczęstszym zaburzeniem w badaniach czynnościowych płuc (12/17) 
było obniżenie wskaźnika dyfuzji dla tlenku węgla (DLCO). U 2 chorych stwierdzono niewydolność oddechową w spoczynku. 
Chorych obserwowano od 6 miesięcy do 19 lat. Samoistną częściową remisję zmian obserwowano u 10 spośród 13 chorych 
nieleczonych, w tym u jednego chorego remisję całkowitą, w 3 przypadkach stwierdzono stabilizację zmian w badaniach radiolog-
icznych, a u kolejnych 4 chorych zastosowano leczenie w postaci płukania całych płuc, uzyskując u 3 z nich poprawę kliniczną oraz 
częściową remisję zmian w badaniach radiologicznych. U jednego chorego pomimo trzykrotnego płukania nie uzyskano poprawy.
Wnioski: Proteinoza pęcherzyków płucnych jest rzadką chorobą śródmiąższową, w większości przypadków o łagodnym przebiegu. 
U 13/17 chorych rozpoznanie ustalono poza Instytutem Gruźlicy na podsatawie badań histopatologicznych wycinków z płuca po-
branych podczas otwartej biopsji płuca, co jest głównie związane z czasem, z jakiego pochodzi większość chorych (1984–2004), 
kiedy to otwarta biopsja płuca była wymaganym badaniem diagnostycznym. Po ustaleniu rozpoznania chorzy byli kierowani do 
Instytutu Gruźlicy w celu ustalenia dalszego postępowania. Najczęściej stwierdzanym zaburzeniem w badaniach czynnościowych 
płuc było obniżenie DLCO. W większości przypadków obserwowano spontaniczną remisję zmian. U czterech chorych z PAP 
o ciężkim przebiegu zastosowano płukanie całych płuc, uzyskując w 3 przypadkach poprawę. 
Słowa kluczowe: proteinoza pęcherzyków płucnych, diagnostyka, przebieg kliniczny, płukanie całych płuc
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Introduction
Pulmonary alveolar proteinosis (PAP) is 
a rare disorder characterised by the accumulation 
of surfactant lipids and protein in the alveolar 
spaces. The incidence of PAP worldwide is es-
timated at approximately 0.2/1,000,000 people 
per year, and the morbidity rate at 3.7/1,000,000 
[1]. According to the National Register of PAP in 
Japan, in 2008, the incidence and morbidity were 
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higher and amounted, respectively, to 0.49 and 
6.2 per 1,000,000 people in the general population 
[2]. The mean age at the moment of diagnosis is 39 
years for men and 35 for women. Among patients 
who smoke cigarettes, the prevalence of PAP is 
more frequent in men (M:W = 2.65:1), whereas 
among non-smokers, it is comparable for both 
sexes (M:W = 0.69:1) [3].
Pulmonary alveolar proteinosis was described 
for the first time in 1958 by Rosen, Castleman B 
and Liebow, who, in histological examinations of 
the material from 26 patients, paid attention to 
the presence of distinctive protein and lipid mate-
rial that positively passed the examination using 
periodic acid-Schiff staining (PAS), accumulated 
in the alveoli and was without the features of 
fibrosis or inflammation [4]. Several years later, 
Gordinier and Larson named this substance sur-
factant [5]. The next 40 years of research showed 
that excessive accumulation of surfactant in 
the alveoli is caused by impaired catabolism of 
alveolar macrophages [6]. In 1994, a correlation 
was found between homeostasis of surfactant 
and granulocyte macrophage colony stimulating 
factor (GM-CSF), which plays a crucial role in the 
pathogenesis of the disorder [7]. 
As was mentioned previously, PAP is charac-
terised by excessive accumulation of surfactant 
in the alveoli. Surfactant includes four proteins: 
apoproteins A, B, C and D, and lipids, such as: 
phospholipids, cholesterol, aminoglycerol and 
free fatty acids. In proteinosis, macrophages 
show many defects, such as impaired motility, 
adherence, chemotaxis, the power of phagocyto-
sis and killing microorganisms, which increases 
the tendency to infections [6]. GM-CSF shortage 
causes macrophage dysfunction and excessive 
accumulation of surfactant in the alveoli [8, 9].
Detection of GM-CSF autoantibodies in se-
rum and bronchial washings (BAL, bronchoal-
veolar lavage) of patients with PAP allowed PAP 
to be classified as an autoimmune disorder [10]. 
Autoimmune pulmonary alveolar proteinosis 
(aPAP) is the most frequent form of the disorder, 
comprising up to 90% of all cases. Apart from 
high-resolution computed tomography (HRCT), 
BAL and histologic examination, diagnosis is 
based on detection of GM-CSF autoantibodies in 
serum or bronchial washings [3]. Secondary PAP 
is a more rare form of the disorder. It develops 
in the course of other diseases or exposures that 
cause an increase in the count or dysfunction of 
alveolar macrophages (less than 10% of all cas-
es). The most rare is the congenital form, caused 
by mutations of genes encoding for surfactant 
proteins or protein transporting ABCA3, and 
developing during the neonatal period [3, 11]. 
Clinical symptoms of PAP are uncharacter-
istic, and its course is usually mild and does not 
impair significantly the function of the lungs. 
A considerable proportion of patients do not 
notice symptoms of the disease despite distinct 
lesions in the lungs, which in some patients 
may regress spontaneously. In cases that require 
treatment, whole lung lavage (WLL) is used [11]. 
Cases of proteinosis have already been pre-
sented in Poland [12–15]; however, they are 
sparse, probably due to infrequent prevalence.
The objective of the study was to present 
the characteristics and the course of PAP in our 
own material, the investigation of diagnostic 
methods and reasons for referral of patients to 
the National Institute of Tuberculosis and Lung 
Diseases, indications for treatment and evaluation 
of efficacy thereof. 
Material and methods
Material included 17 patients with PAP (6 wom-
en and 11 men), 32–56 years of age, hospitalised 
at the Third Lung Department of the National 
Institute of Tuberculosis and Lung Diseases in the 
years 1984–2013. The patients had the following 
examinations performed: chest X-ray (Fig. 1), 
HRCT (15 patients) and lung function tests: blood 
Figure 1. Chest X–ray showing diffuse bilateral alveolar infiltrates
Rycina 1. Badanie RTG klatki piersiowej przedstawiające rozsiane 
obustronne zagęszczenia pęcherzykowe
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gases and plethysmography with determination 
of diffusing capacity of the lung for carbon mon-
oxide (DLCO). In all of the patients bronchoscopy 
was performed, and BAL was done in 7/17. 
In 14 patients open lung biopsy was obtained 
(OLB), and in a further two, some other type of 
lung biopsy. Additionally, one female patient, 
as well as OLB, had the level of serum GM-CSF 
autoantibodies determined. 
Criteria used for WLL treatment were pro-
gression of the disease with dyspnoea that hin-
dered everyday activities and/or hypoxaemia (Pa02 
≤ 60 mm Hg). 
Results
In the presented material, the majority con-
stituted men (64.7%), M:W = 1.8:1. The mean 
age of patients was 42.5 years. Most patients 
(13/17) were diagnosed at other centres, beyond 
the National Institute of Tuberculosis. All of them 
underwent open lung biopsy, and 11 patients 
received definite histological diagnosis. In the 
remaining two patients, unspecified interstitial 
disease (case no 9) or pneumocystis (case no 17) 
were diagnosed. The patients were referred to 
the National Institute of Tuberculosis in order 
to establish further proceedings, including indi-
cation for WLL. One of these patients (case no 9) 
was referred after 12 years of observation, due to 
interstitial disease, and the cause was pneumo-
nia that had not regressed after treatment with 
antibiotics. 4 out of 17 patients were referred in 
order to establish causes of disseminated lesions 
in the lungs. In these cases, diagnosis was made 
at the National Institute of Tuberculosis, based 
on histological examination of lung specimens 
taken during OLB or transbronchial lung biopsy 
(TBLB) (two patients: cases no 8 and 7). In one 
case (no 10), diagnosis was established based on 
the result of BAL. Bronchoscopy was performed 
in all patients, but only 7/17 subjects underwent 
bronchoalveolar lavage; in 6 patients the fluid 
was characteristic and showed positive PAS 
staining. 
The time that passed from the appearance of 
symptoms or detection of changes at chest X-ray 
to the moment of diagnosis was from 1 month to 
12 years. In 7 patients, lesions in the lungs were 
found by accident, in 10/17 — due to ailments. 
The most frequent reason of performing chest 
X-ray was dyspnoea (6 patients), symptoms of 
infection of the respiratory system (3 patients) 
and pain in the chest (1 patient). In physical ex-
amination, only in one patient crepitations at the 
base of the lung and clubbed fingers were found. 
Most patients smoked cigarettes (13/17). 4 out of 
17 patients reported exposure to harmful factors: 
cement dust, wood dust, sawdust and chemical 
compounds — these patients were diagnosed with 
secondary proteinosis (Table 1). The remaining 
patients were not exposed nor did they have 
a disease that favoured proteinosis, so the primary 
form of the disorder was diagnosed. In one pa-
tient who had the test performed, serum GM-CSF 
autoantibodies were found (case no 1). 
In all patients, chest X-ray showed a bi-
lateral macular density located mainly in the 
perihilar area and in lower or upper lung lobes 
(Fig. 1), whereas in 15 patients, HRCT showed 
ground-glass opacities with the symptoms of the 
so-called “crazy paving” pattern, and separated 
areas of healthy parenchyma. In 13/17 patients, 
lesions found at X-ray were symmetrical, and in 
4 patients (cases no 5, 13, 14 and 17) they were 
asymmetrical. Based on HRCT, in 11 cases, ra-
diologists suggested the diagnosis of PAP (Fig. 
1A, B); in 4 patients, they considered another 
interstitial disease: in two subjects (cases no 1 and 
13) — allergic alveolitis, and in the successive two 
patients (cases no 4 and 16) — idiopathic intersti-
tial pneumonia. In cases no 5 and 9, HRCT assays 
were not available and interstitial lung disease 
was diagnosed based on chest X-ray. 
Pulmonary function tests showed ventilation 
disorders with restriction in three patients: in one 
patient — of mild degree, and the other two — of 
moderate degree. Reduced DLCO was found in 12 
out of 17 patients; in 5 patients — of mild degree, 
in 4 — of moderate degree, and in 3 — of severe 
degree. Hypoxaemia (Pa02 < 70 mm Hg, but > 
60 mm Hg) at rest was found in 8 patients, where-
as respiratory insufficiency was diagnosed in 
2 out of 17 patients (Table 2).
The observation time of patients lasted from 
6 months to 19 years (median 4 years). Sponta-
neous partial remission of lesions was observed 
in 10 out of 13 untreated patients (69%) (Fig. 2A, 
B), including one patient with complete remission 
(case no 6), and in 3 cases (30.7%) stabilisation of 
lesions was found at X-ray examination. 
Four patients underwent whole lung lavage: 
in one patient it was performed once, in two pa-
tients — twice and in one patient — three times. 
Improvement in lung function was achieved (Ta-
ble 3), and in three patients, partial remission of 
lesions at chest X-ray was observed (Fig. 2A, B). 
In one patient, despite whole lung lavage per-
formed three times, improvement was not 
achieved. Comparison of the mean functional 
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Table 1. Clinical characteristics of PAP patients in our own material
Tabela 1. Charakterystyka kliniczna chorych na proteinozę pęcherzyków płucnych w prezentowanym materiale własnym
Sex/ 
/age
Cigarette 
smoking
Exposure to 
injurious  
factors 
Time to 
diagnosis 
Symptoms at 
diagnosis
Diagnostic 
method
Date of 
diagnosis 
(year)
Time of 
follow up
Clinical course
1.K/40 – – 24 mth – OBP 2009 4 years SR
2.K/56
.
+ – 3 mth chest pain OBP 2009 4 years S
3.K/49 + – 2 mth respiratory tract 
infection
OBP 2005 8 years SR
4.K/47 – – 3 mth – OBP 2013 6 mth SR
5.K/44 + – ND dyspnoea OBP 1994 19 years SR
6.M/41 – cement dust 2 mth – OBP, BAL 2005 8 years CSR
7.M/53 + – 5 mth – TBLB
BAL
2003 10 years SR
8.M/34 + sawdust 12 mth respiratory tract 
infection
TBLB
BAL
2005 8 years S
9.M/39 + – 3 mth dyspnoea OBP 1972 6 years SR
death during  
infection
10.M/55 + – 4 mth – BAL 2012 7 mth S
11.M/38 + – 1 mth respiratory tract 
infection
OBP 2012 1 year SR
12.M/55 – – 2 mth – OBP 2006 1 year SR
13.M/53 + wood dust 2 mth dyspnoea OBP,BAL 2012 1 year SR
14.M/38 + – 3 mth – OBP 2007 6 lat/years WLL after 8 months 
since the diagnosis 
15.M/32 + – 8 mth dyspnoea OBP 2008 1 year WLL at diagnosis
16.M/42 + mercaptans, 
sulphur 
hydrogen 
chloride
pit-coal dust
12 mth dyspnoea OBP, BAL 2001 11 years WLL after 10 months 
since the diagnosis, 
death probably 
during infection
17.K/49 + – 4 mth dyspnoea OBP,
BAL
2012 6 mth WLL after 3 months 
since the diagnosis
OBP — open lung biopsy; BAL — bronchoalveolar lavage; TBLB — transbronchial lung biopsy; S — stabilizacjastabilisation; SR — spontaneous remission; 
CSR — complete idiopathic remission; WLL — whole lung lavage; ND — no data available
values of the respiratory system in the group 
that underwent lavage and in the group that 
was not classified to WLL, has shown distinct 
differences (Table 4).
Two patients died: one after 6 years of ob-
servation due to infectious complications (case 
no 9), and the second one 11 years after diagnosis 
(case no 16). Thirteen patients are under obser-
vation of the National Institute of Tuberculosis 
and Lung Diseases; these patients do not suffer 
from respiratory system troubles, and three of 
them occasionally have mild infections of the 
respiratory system (cases no 1, 2, 3). There is no 
information about the remaining two patients 
(cases no 12 and 15).
Discussion
Pulmonary alveolar proteinosis is distin-
guished by excessive accumulation of phospho-
lipids, surfactant lipids and protein in the alveolar 
spaces and distal bronchioles, which may lead 
to gas exchange disturbances and sometimes 
to respiratory insufficiency. The symptoms of 
the disorder are unspecific: cough, dyspnoea, 
lowered exercise tolerance and rarely pain of 
pleural nature in the chest. Approximately 20– 
–30% of patients do not have clinical symptoms, 
and lesions in the lungs are found by accident. 
A disproportion between intensive radiological 
pathology and mild clinical symptoms is often 
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Table 2. Pulmonary function test of PAP patients at the time of diagnosis
Tabela 2. Badania czynnościowe układu oddechowego chorych na PPP w chwili rozpoznania
Sex/age VC L (%N) TLC L (%N) DLCO
mmol/min/kPa (%N)
Pa02
mm Hg
1.K/40 3.9 (124%) 5.41 (113.4%) 5.78 (68.9%) 80
2.K/56 3.18 (108%) 4.87 (97%) 6.76 (85%) 80
3.K/49 2.62 (84.3%) 4.15 (82.4%) 5.39 (64.8%) 62.2
4.K/47 3.00 (93.4%) 4.51 (98.6%) 5.26 (67.8%) 64
5.K/44 3.0 (80%) 3.75 (82%) 4.9 (58%) 66
6.M/41 4.55 (99.5%) 6.15 (94.6%) 9.20 (90.6%) 87.5
7.M/53 4.48 (104%) 7.15 (106%) 7.97 (82%) 61.5
8.M/34 5.18 (108.7%) 6.55 (100.7%) 6.06 (57.1%) 75.4
9.M/39 2.95 (57%) 4.53 (67%) 8.45 (82.1%) 68
10.M/55 5.11 (104.7%) 6.92 (95.8%) 7.45 (72.8%) 74.2
11.M/38 6.35 (106.8%) 8.35 (106.2%) 11.05 (90.78%) 75 
12.M/55 3.79 (97.8%) 5.45 (89.2%) 6.24 (72%) 76.9
13.M/53 3.61 (82.7%) 5.54 (85.19) 5.58 (60.05%) 69
14.M/38 2.78 (67%) 4.55 (77.6%) 4.53 (47.9%) 67
15.M/32 3.96 (81.6%) 5.42 (83.4%) 4.23 (39.1%) 61
16.M/42 2.82 (59%) 2.71 (58%) 3.88 (39%) 58
17.K/49 2.75 (86.6%) 3.95 (85.2%) 3.74 (38.8%) 54
VC — vital capacity; TLC — total lung capacity; DLCO — diffusing capacity of the lung for carbon monoxide; Pa02 — arterial oxygen tension
Figure 2. HRCT scan before (A) and after (B) whole lung lavage — visible partial regression of infiltrates
Rycina 2. Badanie tomografii komputerowej wysokiej rozdzielczości przed (A) i po (B) płukaniu płuc — widoczna częściowa regresja zmian
A B
observed [3, 11]. In the study group, clinical 
symptoms occurred in 10 out of 17 patients 
(59%), and they were observed more rarely in 
comparison with other research. For example, 
in the retrospective analysis conducted on 241 
patients with PAP, only 4 subjects (1.6%) did not 
report any ailments [16]. In another study, only 
3 out of 70 patients (4.3%) were asymptomatic 
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Table 4. The comparison between mean parameters of 
pulmonary function test in patients who under-
went WLL, and in patients not classified to WLL
Tabela 4. Porównanie średnich wartości parametrów 
czynnościowych układu oddechowego  
u chorych, u których wykonano płukanie płuc,  
i u chorych nie kwalifikowanych do płukania 
Whole lung lavage
Parameter Yes (N = 4) No (N =13)
Pa02 (mm Hg) 54.75 72.3
FEV1 (%N) 82.3 93.0
VC (%N) 72.4 99.0
TLC (%N) 76.05 94.6
DLCO (%N) 36.12 71.7
Pa02 — arterial oxygen tension; FEV1 — forced expiratory volume in 1 second; 
VC — vital capacity; TLC — total lung capacity; DLCO — diffusing capacity of 
the lung for carbon monoxide
Table 3. The impact of whole lung lavage on respiratory parameters in four patients treated with WLL
Tabela 3. Wpływ płukania całych płuc na parametry oddechowe u 4 chorych leczonych płukaniem całych płuc 
Case, sex/age Parameter Before WLL After WLL
14.M/38 TLC
VC
DLCO
Pa02 [mm Hg]
4.16 L (70.9%N)
2.56 L (64.1%N)
2.96 L (31.5%N)
51
4.40 L (72.2%N)
3.18 L (76.2%N)
4.48 L (46.2%N)
68
15.M/32 TLC
VC
DLCO
Pa02 [mm Hg]
5.42 L (83.4%N)
3.96 L (81.6%N)
4.23 L (39.1%N)
61
4.42 L (67%N)
3.09 L (63%N)
3.63 L (33%N)
46
16.M/42 TLC
VC
DLCO
Pa02 [mm Hg]
2.56 L (55.3%N)
2.5 L (57,2%N)
3.69 L (38.1%N)
58
3.9 L (66.2%N)
3.5 L (67.4%N)
5.4 L (53.2%N)
84
17.K/49 TLC
VC
DLCO
Pa02 [mm Hg]
3.85 L (84.2%N)
2.74 L (86.7%N)
2.74 L (35.8%N)
49
4.26 L (90%N)
2.78 L (85%N)
3.4 L (43%N)
60.7 
TLC — total lung capacity; VC — vital capacity; DLCO — diffusing capacity of the lung for carbon monoxide; Pa02 — arterial oxygen tension
before diagnosis of PAP [17]. However, similar 
results were obtained by Sobiecka et al., who, in 
an analysis of 7 PAP patients, found symptomat-
ic disease in 3 patients (42.8%) [12], and Inoue 
et al., who observed clinical symptoms in 68% 
of 223 patients [2]. The most frequent ailment 
reported by patients with PAP is dyspnoea [3]. 
In the study by Bonella et al., as many as 94% of 
patients complained about dyspnoea and poor 
exercise tolerance, 66% of patients had persistent 
cough, 49% had strength reduction and 43% had 
weight loss [17]. A comparison of the results of 
the chosen studies is presented in Table 5.
In PAP patients, areas of bilateral and sym-
metrical alveolar opacities are usually found at 
chest X-ray. The highest intensification of lesions 
is usually observed in perihilar areas, with omit-
ted costophrenic angle, which is called butterfly 
wings, with the absence of radiological features 
of left ventricular insufficiency. One-sided or 
asymmetric distribution of lesions is rare, simi-
larly to reticular and nodular image of dissemi-
nated lesions [1, 11]. An important examination 
for the diagnosis of the disorder is HRCT, which 
usually shows lesions in the form of ground-glass 
opacities with visible polygonal structures — the 
so-called “crazy paving” pattern (the result of 
accumulation of surfactant lipids and protein 
in peripheral parts of the lobules adhering to 
the interlobar septa, but not real thickening of 
the septa). The areas of filled alveoli are usually 
separated from the right lung parenchyma and 
located irrespective of anatomic borders, making 
a geographical pattern [18]. There is research 
that proves that it is possible to differentiate 
primary from secondary proteinosis, based on 
HRCT examination. Ishii et al. compared HRCT 
examination of 21 patients with aPAP and 21 
patients with a secondary from of the disorder, 
and they found that the areas of geographical 
pattern were present significantly more frequent-
ly in the first group (71% vs. 24%). The “Crazy 
paving” pattern also occurred more often (71% 
vs. 14%), and subpleural location of lesions was 
more frequent, compared to the group of patients 
with secondary proteinosis (71% vs. 33%) [19]. 
All patients from the study group had chest X-ray 
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Table 5. Pulmonary alveolar proteinosis — a comparison of selected published studies 
Tabela 5. Proteinoza pęcherzyków płucnych — porównanie wyników wybranych opublikowanych badań
Parameter Current  
series 
N = 17
[12]
N = 7
[16]
N = 241
[20]
N = 410
[2]
N = 223
[17]
N = 70
Age at diagnosis 42.5 40.7 42 39 51 43
Ratio male to female 1.8 0.4 2.2 2.6 2.0 1.3
Primary PAP (%) 76 86 ND ND 90 91
Secondary PAP (%) 23 14 ND ND 10 9
Time to diagnosis (months) 1–24 8–77 ND 3–19 4–36 1–36
Spontaneous remission (%) 69 57 ND 6 28 7
Cigarette smoking (%) 76.4 71.4 ND ND 56 49
Exposure to injurious factors (%) 23.5 14 ND ND 26 54
Pa02 mm Hg (range) 54–87 51–80 ND 46–70 58–85 36–96
Whole lung lavage (%) 23.5 0 28 54 ND 90
Small volumes fluid lung lavage (%) 0 43 31 0 ND 0
Diagnostic method 
Autopsy (%)
Surgical biopsy (%)
Transbronchial biopsy (%)
Bal (%)
0
82
11.7
6
0
100
0
0
ND 
ND 
ND 
72
11
71
10
4
0
7.2
12
70
0
20
29
76
ND — no data available
performed, and 15 patients had HRCT, but only 
in 11/15 cases radiologists implied diagnosis of 
PAP. In the remaining 4/15 patients they suspected 
another interstitial disease (allergic alveolitis and 
idiopathic interstitial pneumonia). 
In PAP, ventilation disturbances of restrictive 
nature with lowered total lung capacity (TLC) 
may occur, but the most frequent disturbance that 
correlates with the disease severity is lowered 
DLCO [20]. Bonella et al., in their analysis of 70 
patients with PAP, found lung dysfunction man-
ifesting itself in lowered TLC and DLCO in 60% 
and 92% of patients, respectively [17], whereas in 
a Japanese study of 223 patients, the mean value of 
DLCO amounted to 68.6% [2]. In the present study, 
among 17 patients, in 3 (17.6%) — restrictive dis-
orders were found, and in 12 (70.5%) — impaired 
DLCO, including 3 patients (17.6%) with severe 
DLCO decrease. Due to gas exchange disorders 
caused by the presence of surfactant in the alve-
oli, hypoxaemia often occurs, worsening during 
physical exertion [9, 10]. In the present study, 
in 10 out of 17 patients, hypoxaemia at rest was 
observed, including 2 patients who met criteria 
of respiratory insufficiency (Pa02 < 60 mm Hg). 
Surgical lung biopsy was thought to be a gold 
standard of diagnosis of PAP [20]. However, cur-
rent guidelines imply that an appropriate history, 
characteristic image at HRCT and typical results 
of the examination of bronchoalveolar lavage fluid 
are sufficient criteria for establishing diagnosis, 
without TBLB or OLB [21]. Detection of GM-CSF 
autoantibodies is an additional argument for PAP 
diagnosis, and it also confirms the autoimmune 
nature of the disease [22]. PAP is the only inter-
stitial lung disease that can be diagnosed based 
on BAL examination. The BAL fluid is an opaque, 
iridescent substance, and a light microscope 
shows three characteristic features: the presence 
of acellular corpuscles staining pink during the 
examination using PAS staining, but not staining 
with alcian blue, which differs them from the 
mucus, the presence of foam macrophages filled 
with PAS-positive substance, and the presence 
of amorphous debris representing multistratified 
structures and lamellar corpuscles. In cases when 
the HRCT image indicates PAP, and BAL shows 
three of the above-mentioned features, it may be 
considered to be diagnostic [23]. Bonella et al., 
who analysed a group of 70 patients with PAP, 
used bronchoscopy and BAL as basic diagnostic 
methods, which resulted in the diagnosis of 83% 
of patients (in 49% of patients, BAL was a suffi-
cient examination; in the remaining subjects, in 
addition, TBLB was performed). Open lung biopsy 
was necessary only in 20% of patients [17]. In 
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another analysis that included 223 PAP patients, 
in 58.7% of subjects, diagnosis was based on HRCT 
and BAL, and surgical biopsy was performed only 
in 7.2% of patients [2]. In the study by Sobiecka et 
al. conducted between 1989 and 1999, all patients 
underwent surgical lung biopsy [12]. In the present 
paper, in the majority of patients (14/17), diagnosis 
was also confirmed by histological examination 
of specimens taken during open lung biopsy per-
formed in 13 cases, and in two cases — during 
TBLB. Only in one patient, diagnosis was made 
based on the result of the examination of BAL fluid 
(lung biopsy was not performed). Bronchoalveolar 
lavage was performed in 7 patients, and in 6 of 
them the fluid was typical and showed positive 
PAS staining. It should be emphasised that 13 out 
of 14 patients who were diagnosed after OLB, after 
the procedure were referred to the National Insti-
tute of Tuberculosis in order to establish further 
proceedings. The second factor that influenced 
the high proportion of diagnoses based on OLB 
is the period of time in which the patients were 
diagnosed — a great part of the patients were seen 
between 1984 and 2004, when OLB was required 
to establish diagnosis of the disease.
It is known that the most frequent form of 
PAP is autoimmune, the diagnosis is based on 
detection of serum GM-CSF autoantibodies. Test 
sensitivity for aPAP is 100% and specificity 98% 
[10]. However, such a test is not commonly avail-
able. Nowadays, efforts are being made so that the 
test could be used in everyday clinical practice. 
While waiting for the possibility to perform the 
test in Poland, blood samples were taken from 
6/17 recently hospitalised patients to examine the 
presence of GM-CSF autoantibodies. One patient 
(case no 1) had the test performed in Germany, 
and as a result, autoantibodies were detected, and 
consequently aPAP was diagnosed. 
Recent examinations have also shown the pres-
ence of autoantibodies in some patients with sec-
ondary PAP, which is connected with inflammatory 
or neoplastic diseases, but these autoantibodies do 
not neutralise GM-CSF. In patients with secondary 
PAP connected with exposure to harmful factors, 
GM-CSF autoantibodies are rarely detected [3, 11]. 
In 4/17 (23.5%) patients (cases no 6, 8, 13 and 
16), evidence of long-term exposure to harmful 
factors was found, and this was recognised as one 
of the causes of secondary proteinosis. In these 
patients, at the present time, the secondary from 
of the disease was diagnosed. However, when 
analysing these cases it should be remembered 
that the development of aPAP is possibly caused 
by the influence of dust and external factors [22]. 
There are different opinions concerning the 
clinical significance of GM-CSF autoantibodies. 
Some researchers show a lack of correlation be-
tween serum concentration and disease severity, 
but show such correlation between concentration 
in BAL fluid and markers of the disease severity, 
such as blood oxygen partial pressure, DLCO or 
advanced lesions seen on HRCT [24]. Others con-
firm the relation between serum autoantibodies 
concentration and the course of the disease [17]. 
It is indisputable that the discovery of GM-CSF 
autoantibodies has opened up new possibilities 
for treatment of proteinosis in the form of subcu-
taneous or inhaled recombinant GM-CSF. In spite 
of tremendous interest in this form of therapy, 
to date there have not been any trials conducted 
concerning optimal drug doses, the length of 
treatment necessary for complete regression of 
changes, or the safety of applied treatment. In 
2012, a meta-analysis including research pub-
lished between 1996 and 2010 was made avail-
able. It showed that the proportion of responses 
to treatment with GM-CSF was 43%-92%, and 
that it was slightly higher in patients treated 
with inhaled drugs, compared to patients treated 
with subcutaneous injections. After finishing the 
treatment, the disease recurred in 29.7% of pa-
tients, and recurrences were more frequent among 
the patients treated subcutaneously (43.9% vs. 
15.2%). No significant long-term toxicity was 
shown, the most frequent adverse effects were 
fever, erythema in the place of injection, and in 
patients treated with inhaled drugs — infections 
of the respiratory system [25]. 
The most effective and safe method of tre-
atment of PAP is still whole lung lavage, which 
removes surfactant-like material from the alveoli 
[11, 26, 27]. The first procedure was performed 
in 1965 by Ramirez R. J. It is performed in the 
operating theatre under general anaesthesia. The 
lung that is going to be washed is excluded from 
respiration, and sterile, heated physiological 
saline is administered. The capacity of a single 
dose of liquid should correspond to preoperative 
functional residual capacity (FRC) — usually it 
is 500–1000 ml. To completely clean the lung of 
lipid material, approximately 20–40 L of physiolo-
gical saline should be used at a single time. At the 
end of lavage, the residue of the liquid is sucked 
off and 100% oxygen is given. The procedure 
lasts for 3–5 hours and has to be performed by 
well trained staff in a properly equipped opera-
ting theatre [13]. There are no precise guidelines 
concerning the use of WLL, but according to the 
majority of authors, these are hypoxaemia (Pa02 
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Figure 3. Management algorithm in PAP 
Rycina 3. Algorytm postępowania w proteinozie pęcherzyków płucnych
< 65 mm Hg or < 60 mm Hg) or saturation below 
90%, the growth of alveolo-capillary gradient of 
oxygen partial pressure above 40 mm Hg, pulmo-
nary shunt exceeding 10–12% and/or dyspnoea 
limiting daily activities of the patient [26, 27]. 
Similar classification criteria were adopted in the 
study group (Pa02 < 60 mm Hg, dyspnoea), where, 
among 17 patients, WLL was applied only in 4 
(23.5%). In 3 patients (75%), clinical, radiological 
and gasometric improvement and improvement of 
functional parameters were achieved, whereas in 
one patient, despite WLL being performed three 
times, no improvement occurred. The frequency 
of indications for WLL in the study group was 
lower in comparison with other studies. In the 
analysis of 70 patients conducted by Bonella et 
al., lavage was performed in 63 patients (90%), 
and in 40 patients (63.5%) improvement was 
achieved after the first procedure [17]. In his stu-
dy, classification criteria for treatment were more 
liberal; they classified to WLL patients with Pa02 
< 70 mm Hg and clinical symptoms in the form 
of dyspnoea. In another study, among 223 aPAP 
patients, 142 people (63.6%) underwent treatment 
with lavage [16]. The algorithm of treatment in 
PAP is presented in Figure 3.
The alternative method to WLL is the lavage 
of lung segments with small quantities of phy-
siological saline during bronchofibroscopy. This 
method is less invasive and does not require 
access to an operating theatre. The procedure 
consists of lavage of separate lung segments with 
small quantities of saline (50–100 mL), with the 
total volume of solution up to 2 L during one 
session. The procedure should be repeated 2–5 
times. Sobiecka et al. observed radiological im-
provement in 2 out of 3 PAP patients classified 
for treatment with lavage with small volumes of 
saline [12]. However, most authors conclude that 
this method is ineffective in patients with severe 
PAP, and contrary to WLL, its impact on oppor-
tunistic infections has not been proven [28]. In 
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2003, Wiatr et al. described a 42-year-old patient, 
in whom improvement was not achieved after the 
use of lavage with small quantities of liquid repe-
ated for two successive days. Whereas, a twofold 
WLL resulted in distinct clinical and radiological 
improvement [13]. In a meta-analysis including 
241 patients with PAP, 142 patients underwent 
treatment with small quantities of liquid or WLL 
with equal frequency, and the two methods sho-
wed comparable efficacy [16]. 
PAP patients have a good prognosis. A ret-
rospective analysis showed that 5-year survival 
is more frequent in patients treated with lavage, 
compared to untreated patients (94% vs. 85%). 
The most frequent cause of death was respira-
tory insufficiency in the course of the disease 
(72%), followed by infections (18%) [20]. It was 
shown that the median time of remission after 
WLL is 15 months, and approximately 20% of 
patients need an additional lavage by the end 
of a 3-year period [20]. In a recently published 
study of 223 aPAP patients from Japan, no death 
occurred during a 5-year observation period, 
and severe infections were found only in 4% of 
patients [2]. In the study group, recurring in-
fections of the respiratory system, usually with 
a mild course, were observed in 5/17 patients. 
Two patients died — one due to staphylococ-
caemia (6 years after diagnosis), the second one 
— presumably also due to infection — 11 years 
after diagnosis. The proportion of idiopathic 
remissions obtained in the study group was 
higher in comparison with other studies — it 
accounted for 77%, whereas, for example, in the 
analysis by Inoue it was 28% [2]. Stabilisation 
of the disease was observed in 23% of patients 
(3/13), compared to 64% in the study by Inoue 
[2]; in our study, the proportion of patients who 
needed whole lung lavage was also lower in 
comparison with other publications (23.5% vs. 
54% or 90%) [17, 20].
Conclusions
Pulmonary alveolar proteinosis is a rare in-
terstitial disorder, usually with a mild course and 
mild clinical symptoms. Radiological image at 
HRCT is so typical that in the majority of cases, 
it is the deciding factor for diagnosis. According 
to recent guidelines concerning diagnostic and 
therapeutic management, the examination of 
bronchoalveolar lavage fluid showing the pres-
ence of PAS-positive substances is sufficient to 
establish a final diagnosis [21]. At that moment, 
the respiratory system function test, especially 
Pa02 and DLCO, and ailments of the patient are 
of crucial importance. Decreased lung function 
parameters or intensive dyspnoea, which were 
observed in a small number of patients, are an 
indication for evacuation of surfactant lipids 
and protein by the use of whole lung lavage. It is 
also vital to treat recurrent infections that may be 
a direct cause of death. However, in the majority 
of cases, prognosis is good. 
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